MemStim-home: Home-based Brain Stimulation for Memory

Sponsor
Hebrew SeniorLife (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT04783350
Collaborator
(none)
20
1
1
29.8
0.7

Study Details

Study Description

Brief Summary

The proposed project aims to systematically examine the feasibility of remote, caregiver-led tACS for older adults who are vulnerable to memory decline.

Condition or Disease Intervention/Treatment Phase
  • Device: Transcranial alternating current stimulation (tACS)
N/A

Detailed Description

This is a feasibility study, which will include older adult participants (Ps) with memory deficits together with willing and able administrators (As) to administer tACS to the participants. This study will include 20 older Ps and 20 As to assess the feasibility of deploying home-based tACS in larger clinical trials, and to prepare for the development and implementation of such trials. The proposed project will systematically examine the feasibility of remote, caregiver-led tACS for older adults who are vulnerable to memory decline. This study will provide data to support the safety and effectiveness of home-based tACS in this population and will lead to future research to increase access of tACS as a part of memory decline prevention and treatment for older adults who have more difficulty reaching a clinic for treatment due to disability or who live more remotely.

Study Design

Study Type:
Interventional
Actual Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Home-based Transcranial Alternating Current Stimulation (tACS) for Older Adults at Risk of Memory Decline
Actual Study Start Date :
Jul 6, 2020
Anticipated Primary Completion Date :
Dec 31, 2022
Anticipated Study Completion Date :
Dec 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Transcranial alternating current stimulation (tACS)

Participants (Ps) will undergo 20min of daily home-based tACS intervention at 40Hz over the left angular gyrus for 4 weeks by trained administrators (As) (phase 1). In case of cognitive and mental improvement participants will undergo further 10 weeks of 20 minutes session of tACS daily (phase 2). Additionally, those P/A pairs who completed the 14 weeks of home-based tACS intervention and express an interest in an open label extension may be enrolled in further 34 weeks of 20 minutes tACS sessions.

Device: Transcranial alternating current stimulation (tACS)
tACS will be administered to the left angular gyrus at gamma frequency to improve cognitive functioning (MoCA score) and resting-state EEG signatures.
Other Names:
  • non-invasive brain stimulation
  • Outcome Measures

    Primary Outcome Measures

    1. Clinical Evaluation and Cognitive Assessment [48 weeks]

      a trained clinician will administer the Montreal Cognitive Assessment (MOCA) to characterize cognitive status and the level of dementia

    2. Electroencephalography (EEG) measures [48 weeks]

      High-density EEG (257 channels) will be recorded before and after the tACS intervention and changes in spatiotemporal dynamics in different frequency bands (theta, alpha, beta, gamma) will be assessed

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    55 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    Participants (Ps)

    • willing and capable to give informed consent for the participation in the study after it has been thoroughly explained

    • able and willing to comply with all study requirements

    • an informed consent form was signed

    • able to read, write, and communicate in English

    • able to identify an eligible administrator to participate with them in the study

    Administrators (As)

    • at least 21 years of age

    • able to read, write, and communicate in English

    • self-reported computer proficiency and willingness to learn how to use tACS as defined by "yes" answers to the questions "Do you feel comfortable using a computer?" and "Are you willing to be the primary caregiver for a participant and learn how to administer tACS?"

    • stated availability during weekdays throughout the study period to administer tACS to the Ps

    Exclusion Criteria:

    Participants (Ps)

    • major psychiatric co-morbidity including major depressive disorder, schizophrenia or psychosis

    • blindness or other disabilities that prevent task performance

    • contraindications to tACS, as recorded on a standardized screening questionnaire, which include a reported seizure within the past two years, use of neuroactive drugs, self-reported presence of specific implanted medical devices (e.g., deep brain stimulator, medication infusion pump, cochlear implant, pacemaker, etc.)

    • the presence of any active dermatological condition, such as eczema, on the scalp a score of 18 or less on the Montreal Cognitive Assessment (MoCA) during the in-person screen

    • an inability to understand study procedures following review of the Informed Consent form

    • Understanding will be assessed by asking the participant to answer the following three questions: 1) What is the purpose of this study? 2) What are the risks of study involvement? 3) If you decide to participate, are you allowed to withdraw from the study at any time? Answers will be recorded by study personnel on the "Assessment of Protocol Understanding" form (see attached). Insufficient understanding will be defined by one or more incorrect answers, as determined at the discretion of the investigator

    Administrators (As)

    • mild cognitive impairment defined by a MoCA score ≤26 during the in-person screen

    • insufficient understanding of study procedures following review of the Informed Consent form

    • Understanding will be assessed by asking the participant to answer the following three questions: 1) What is the purpose of this study? 2) What are the risks of study involvement? 3) If you decide to participate, are you allowed to withdraw from the study at any time? Answers will be recorded by study personnel on the "Assessment of Protocol Understanding" form (see attached). Insufficient understanding will be defined by one or more incorrect answers, as determined at the discretion of the investigator.

    • poor eyesight, severe arthritis in the hands, pain, deformity or other condition that interferes with successful administration of tACS

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Hinda and Arthur Marcus Institute for Aging Research Boston Massachusetts United States 02131

    Sponsors and Collaborators

    • Hebrew SeniorLife

    Investigators

    • Principal Investigator: Alvaro Pascual-Leone, Dr., Hinda and Arthur Marcus Institute for Aging Research

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Alvaro Pascual-Leone, Senior Scientist, Hebrew SeniorLife
    ClinicalTrials.gov Identifier:
    NCT04783350
    Other Study ID Numbers:
    • Pro00044646
    First Posted:
    Mar 5, 2021
    Last Update Posted:
    Jun 22, 2022
    Last Verified:
    Jun 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Keywords provided by Alvaro Pascual-Leone, Senior Scientist, Hebrew SeniorLife
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 22, 2022